Nebracetam
 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H16N2O |
| Molar mass | 204.273 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
  (what is this?) (verify) | |
Nebracetam is an investigational drug of the racetam family that is a M1 acetylcholine receptor agonist in rats.[1] Based on a human leukemic T cell experiment in 1991, it is believed to act as an agonist for human M1-muscarinic receptors.[2] It is also believed to act as a nootropic, like many other racetam drugs.[3] A chemoenzymatic method of synthesis was reported in 2008.[4] As of 2023[update], human trials have not yet been conducted.
See also
[edit]References
[edit]- ^ Takeo S, Hayashi H, Miyake K, Takagi K, Tadokoro M, Takagi N, et al. (June 1997). "Effects of delayed treatment with nebracetam on neurotransmitters in brain regions after microsphere embolism in rats". British Journal of Pharmacology. 121 (3): 477–484. doi:10.1038/sj.bjp.0701161. PMC 1564714. PMID 9179389.
- ^ Kitamura Y, Kaneda T, Nomura Y (January 1991). "Effects of nebracetam (WEB 1881 FU), a novel nootropic, as a M1-muscarinic agonist". Japanese Journal of Pharmacology. 55 (1): 177–180. doi:10.1254/jjp.55.177. PMID 2041225.
- ^ Gabryel B, Pudełko A, Trzeciak HI, Cieślik P (2000). "Effect of nebracetam on content of high-energy phosphates and morphometry of rat astrocytes in vitro. Comparison with piracetam". Acta Poloniae Pharmaceutica. 57 (4): 289–298. PMID 11126618.
- ^ Yamashita S, Mase N, Takabe K (2008-09-22). "Chemoenzymatic total synthesis and determination of the absolute configuration of (S)-nebracetam". Tetrahedron: Asymmetry. 19 (18): 2115–2118. doi:10.1016/j.tetasy.2008.09.004. ISSN 0957-4166.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |